Semaglutide 2.4 mg for managing overweight and obesity (TA875)
Safety and Tolerability Cerebrolysin: Well-Established Safety Profile Cerebrolysin benefits from decades of post-marketing surveillance and clinical trial safety data: Clinical Trial Safety: Across multiple RCTs, Cerebrolysin has demonstrated a tolerability profile comparable to placebo in most studies, with adverse events generally mild and transient Common Side Effects: Injection site reactions, dizziness, headache, and nausea are the most frequently reported adverse events at standard clinical doses Serious Adverse Events: Rare at therapeutic doses
In neuronal senescence model studies, the active ingredient of the product can cross the blood-brain barrier (and act directly on neurons in vitro), increase NAD+ levels in nerve cells, protect mitochondrial function, reduce neuronal apoptosis, and promote the synthesis and release of neurotransmitters (such as dopamine and acetylcholine), thereby improving signal transduction in nerve cells
Temperature exposure Moisture contact Light exposure Repeated handling Transport conditions Product format and excipients Lyophilised Format and Storage GHK-Cu 50mg is supplied in lyophilised form
Dihexa is ideal for those seeking sharper cognition, faster recall, and long-term neuroprotection